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Objective: This multicenter study retrospectively analyzes the data on 114
patients with protein-losing enteropathy after Fontan-type surgery. Special
attention was given to the different treatment strategies used and their
effect on outcome. Methods and results: In 35 participating centers 3029
Fontan operations were performed. The incidence of protein-losing enter-
opathy in the survivors was 3.7%. The median age at Fontan-type surgery
was 8.2 years (range: 0.6 to 32.9 years). Median age at diagnosis of
protein-losing enteropathy was 11.7 years with a median time interval
between surgery and diagnosis of 2.7 years (range: 0.1 to 16.4 years). Most
patients had edema (79%) and effusions (75%). Hemodynamic data re-
vealed a mean right atrial pressure of 17 6 SD 5.3 mm Hg with a cardiac
index of 2.4 6 0.8 L/min/m2. Medical treatment only (n 5 52) resulted in a
complete resolution of symptoms in 25%, no improvement in 29%, and
death in 46%. Surgical treatment (n 5 52) was associated with relief of
protein-losing enteropathy in 19%, no improvement in 19%, and death in
62%. In 13 patients 16 percutaneous interventions were performed. This
resulted in symptomatic improvement after 12 interventions and no
improvement after 4 interventions. Conclusions: We conclude that the
current treatment of protein-losing enteropathy after Fontan operation is
associated with a very high mortality and morbidity rate. Preventive
strategies and new therapeutic approaches are necessary. (J Thorac
Cardiovasc Surg 1998;115:1063-73)
Protein-losing enteropathy (PLE) is a rare butlife-threatening complication after the Fontan
operation. It is speculated that the elevated systemic
venous pressures associated with the Fontan circu-
lation cause the intestinal protein loss by increased
pressures in the enteric lymphatic system.
Only limited information is presently available on
the incidence, the predisposing factors and the
hemodynamic profile of patients who have had the
Fontan operation and in whom PLE develops.1, 2
Different treatment strategies have been proposed
for PLE after the Fontan operation, but their effect
on the outcome remains largely unknown. Reports
on successful management are limited. For the
management of these difficult conditions it is, how-
ever, crucial to know which approach is doomed to
fail so that alternative treatment options can be
explored. The present study is a retrospective mul-
ticenter study reviewing the incidence, hemodynam-
ics, treatment strategies, and outcome of patients
with PLE after Fontan-type surgery.
Materials and methods
Center recruitment. This study is a retrospective mul-
ticenter study. The centers were recruited either by e-mail
through Pediheart (a server to which professionals in-
volved in the health care of patients with congenital heart
disease can subscribe [pediheart@medisun.ucsfresno.
edu]) or by regular mail. At the time the study was
announced, 588 persons received the e-mail message.
Regular mailing was sent to all 470 members of the
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European Association of Pediatric Cardiologists. Thirty-
five centers (listed at the end of the paper) finally submit-
ted data. Collection of data was started in August 1995
and stopped in December 1996.
Patient selection. A study questionnaire was filled out
for each patient who had had Fontan-type surgery and in
whom clinical symptoms of documented hypoproteinemia
(edema, effusions) due to PLE developed. Other causes of
hypoproteinemia such as liver failure and renal protein
loss needed to be excluded.
In addition, the centers were asked to submit data as to
the number of Fontan operations that had been per-
formed, perioperative mortality rates, and follow-up pro-
cedures. This allowed an assessment of the incidence of
PLE after Fontan-type surgery. Because of incomplete
data sets, detailed information could not be gathered on
the other patients without PLE who have had Fontan
operations.
Fontan surgery. Descriptive statistics were performed
on the data. The primary outcome variable was the effect
of treatment on the PLE (death, no change, improved,
cured). In every patient with PLE, all the requested
information was obtained. Student’s t test, x2 test, corre-
lation analysis with Fisher’s r to z transformation were
applied where appropriate. Survival analysis was per-
formed by the Kaplan-Meier estimation. For the compar-
ison of subgroup survival Mantel-Cox log rank analysis
was performed. Statistical analysis was performed with the
software programs Statview 4.5 (Abacus Concepts, Berke-
ley, Calif.) and GB-stat 6.0 (Dynamic Microsystems, Silver
Spring, Md.).
Results
General patient data. In total, 3029 Fontan-type
operations were performed in 35 participating cen-
ters. The operations were performed between 1975
and 1995. The number of Fontan operations per-
formed in each center ranged between 4 and 839
(median: 54). The early mortality rate (,30 days
after surgery) ranged between 0% and 41.7 %, with
a mean of 13.3 6 standard deviation 9.5%. The total
number of patients in follow up who have under-
gone Fontan operations was 2584 (median for each
center: 40; range: 3 to 764 patients). PLE was
diagnosed in 114 patients. The 3.8% incidence of
PLE is relative to the total number of Fontan-type
operations and 4.2% relative to the number of early
survivors. The incidence of PLE relative to the total
number of Fontan operations in each center varied
between 0% and 25%. Neither the number of
Fontan operations performed in each center nor the
early mortality rates correlated significantly with the
incidence of PLE.
Data on all 114 patients with PLE were obtained
(72 male and 42 female). The cardiac diagnosis was
tricuspid atresia in 36 patients (31.6%), double-inlet
left ventricle in 33 patients (29%), and other forms
of “complex univentricular heart” in 45 patients
(39.4%). The last group contained diverse complex
congenital heart defects such as atrioventricular
canal–type of malformation (8), double-outlet right
ventricle (8), mitral atresia (4), single-inlet ventricle
(4), L-transposition of the great arteries plus severe
pulmonary stenosis (4), double-inlet right ventricle
(2), hypoplastic left heart syndrome (2), pulmonary
atresia with intact ventricular septum (2), and other
forms of “functional univentricular heart” (10).
Heterotaxy syndrome was present in three pa-
tients: two patients with asplenia and one patient
with polysplenia. Four patients had situs inversus,
and one patient had situs ambiguus.
In 97 of 114 patients (85%) palliative surgery was
performed before the Fontan operation. The differ-
ent types of pre-Fontan palliation and the age at
which pre-Fontan surgery was performed are sum-
marized in Table I. In total, 62 of 114 (53%)
patients, when initially seen, had low pulmonary
blood flow that caused cyanosis; 33 of 114 (28%)
Table I. Pre-Fontan surgery
Palliation
1
Palliation
2
Palliation
3
Palliation
4
Age (yr 6 SD) 2.5 6 4.5 4.7 6 4.8 7.3 6 6.1 3.7 6 1.6
Type of surgery
Blalock-Taussig 33 25 0 1
Banding PA 24 5 0 0
Central shunt 10 6 4 2
Glenn 7 1 2 0
Bidirectional Glenn 1 6 0 0
Atrial septostomy 4 0 1 0
Norwood I 3 0 0 0
Commisurotomy PV 4 0 1 0
VSD closure 1 0 0 0
VSD enlargement 1 0 1 0
Mitral valve surgery 1 1 0 0
Other 7 3 5 1
Total 96 47 14 4
SD, Standard deviation; PA, pulmonary artery; PV, pulmonary valve; VSD,
ventricular septal defect.
Table II. Pre-Fontan hemodynamic data
Number Mean SD Minimum Maximum
Sat Ao 99 81.5 6.7 51.0 96.0
PAP (mean) 83 16.4 7.2 6.0 41.0
PVR 62 1.9 1.2 0.2 5.6
Nakata 42 291.0 95.4 100.0 508.0
McGoon 28 2.1 0.8 1.0 3.9
Cardiac index 47 4.1 1.4 1.2 7.4
Mean LAP 86 9.0 5.2 2.0 28.0
SD, Standard deviation; Sat Ao, saturation aorta; PAP, pulmonary artery
pressure; PVR, pulmonary vascular resistance; LAP, left atrial pressure.
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patients had high pulmonary blood flow that re-
quired a banding type of operation to protect the
pulmonary circulation. In this series, initial banding
was performed at a median age of 0.6 years (range:
3 days to 3.4 years); five patients were banded twice.
In 19 of 114 (19%) patients, the initial lung flow was
“balanced” and surgical palliation before the Fon-
tan operation was not performed.
Pre-Fontan hemodynamic data. A preoperative
cardiac catheterization was performed in 106 of
114 patients (93%). Table II summarizes the
hemodynamic measurements obtained before the
Fontan operation. Data on preoperative atrioven-
tricular valve regurgitation were available on 92
patients. Of 92 patients, atrioventricular valve
regurgitation was described as absent in 64
(69.5%) patients, mild in 18 (19.5%) patients,
moderate in 5 (5.5%) patients, and severe in 5
(5.5%) patients.
Fontan-type surgery. Fontan-type surgery was
performed at a median age of 8.2 years (range: 0.6
to 32.9 years). The operation was performed in 70 of
114 patients (61.4%) before 1987 and in 44 of 114
patients (38.6%) after 1987.
The time distribution of the series reflects
changes in surgical techniques. In 114 patients, an
atrioventricular connection was performed in 22
(19.3%); an atriopulmonary connection was per-
formed in 75 (65.8%); and a total cavopulmonary
connection (with total or subtotal exclusion of the
right atrium) was performed in 17 (14.9%). Thus no
type of connection is free of PLE after Fontan
surgery.
The early postoperative course was characterized
by a median intensive care unit stay of 8 days (range:
2 to 50 days), a median postoperative hospitalization
duration of 26 days (range: 8 to 150 days), and a
requirement for chest tube drainage during 12 days
(median range: 0 to 135 days). Postoperative com-
plications were ascites (n 5 17), renal failure (n 5
13), arrhythmia (n 5 26), respiratory problems (n 5
8), wound infection (n 5 5), unilateral diaphrag-
matic paralysis (n 5 3), and neurologic complica-
tions (n 5 2).
In 12 patients additional surgery was performed
between the initial Fontan operation and the time
PLE was diagnosed. This included closure of a leak
in the atrioventricular-valve patch (4), atrioventric-
ular-valve replacement (3), pacemaker implantation
(3), plication of the diaphragm (1), and aortic valve
replacement (1). In one patient angioplasty of the
pulmonary artery was performed.
Clinical diagnosis of PLE and hemodynamic eval-
uation. As mentioned in the Materials and methods
section, PLE was defined in this study as the occur-
rence of clinical symptoms related to documented
hypoproteinemia caused by intestinal loss. Other
causes of hypoproteinemia had to be excluded.
Moreover, subclinical gastrointestinal protein loss
was not considered an inclusion criterion for the
present study.
At the time of diagnosis of PLE, the patients had
edema (79%), ascites (53%), pleural effusion(s)
(22%), and/or chronic diarrhea (11%). Other symp-
toms or clinical findings present at the time of
diagnosis were dyspnea (5%), fatigue (3.5%), ab-
dominal fullness (5%), carpopedal spasms (1.7%),
and a pericardial effusion (1.7%). The other com-
plications are summarized in Table III.
The median time interval between Fontan-type
surgery and the occurrence of PLE was 2.7 year
(range: 1 month to 16.4 years).
In all patients either total protein and/or serum
albumin measurements were obtained. In 89 of 114
patients the serum albumin level at the time of
diagnosis was 2.4 6 0.6 gm/dl (normal value: 3.5 to
5.5 gm/dl). In 55 of 114 patients the total protein
level was 4.3 6 0.8 gm/dl (normal value: 5.5 to 8.0
gm/dl). The gastrointestinal protein loss was quan-
tified by calculating the a1-antitrypsin clearance in
Table III. Other complications in patients with
PLE
Complication
No. of
patients (%)
Hypocalcemia 38 (33)
Infections 19 (16)
Sepsis 9
Respiratory infections 8
Cholecystitis 2
Recurrent cellulitis 3
Herpes simplex infection 1
Pneumococcal peritonitis 1
Thromboembolic complications 21 (18)
Right atrial thrombus 12
Pulmonary artery thrombus 4
Ventricular thrombus 2
Cerebrovascular accident 5
Pulmonary embolism 5
Arrhythmia 32 (28)
Atrial flutter 9
Atrial fibrillation 6
Supraventricular tachycardia 8
Junctional rhythm 4
Supraventricular ectopy 1
Atrioventricular block 4
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27 patients. The mean value was 432 6 370 ml/24 hr
(normal value , 27 ml/24 hr). In seven patients
gastrointestinal protein loss was quantified by intra-
venously administered 51chromium-labeled albu-
min. An increased enteric protein loss was demon-
strated by an increased excretion of the labeled
albumin in the stools: 22.7% 6 7.2% of the injected
radioactive label (normal: ,2.0%).
In 83 (73%) of 114 patients hemodynamic evalu-
ation by cardiac catheterization was performed after
PLE was diagnosed. Table IV summarizes the basic
hemodynamic measurements obtained during cath-
eterization. These data are, however, difficult to
interpret because nearly all of the patients were
receiving significant doses of diuretics at the time of
catheterization. Of special note are the mean car-
diac index of 2.4 6 0.8 L/kg/min and the mean right
atrial pressure of 17.0 6 5.3 mm Hg. In 29 patients
a gradient was reported to be present in some part
of the Fontan connection. In 22 patients numeric
data for gradients were available (mean: 4.3 6 3.0
mm Hg; range: 2 to 15 mm Hg). Other findings of
relevance included intrapulmonary shunting (5), re-
sidual connection single ventricle–pulmonary artery
(3), atrioventricular valve patch leak (1), obstruction
of pulmonary venous return (2), obstruction of the
atrial baffle from the hepatic veins to the pulmonary
artery (1), venovenous collaterals (3), residual Bla-
lock-Taussig shunt (1), diaphragmatic paralysis (3),
and coronary artery ligation (1). Atrioventricular
valve regurgitation was present in 29 patients (se-
vere [5], moderate [12], and mild [12]). Ventricular
dysfunction was present in 24 patients (severe [9],
moderate [9]). In two patients a marked bradycardia
associated with sinus node dysfunction and nodal
rhythm was present.
Treatment and outcome of PLE. Patients in
whom PLE develops after the Fontan operation
have a poor prognosis with a 5-year survival of 59%
and a total mortality rate of 50% in the present
study. The Kaplan-Meier survival analysis is shown
in Fig. 1.
In the treatment of PLE, a wide variety of differ-
ent approaches have been tried. Three main treat-
ment options can be identified. First, a purely
noninvasive treatment consisting of drug treatment
(diuretics, afterload reduction, inotropic agents, and
steroids) and diet (low fat and high protein) and/or
protein infusions can be used. Second, surgery can
be performed to improve the Fontan hemodynam-
ics. Third, a nonsurgical interventional approach can
be used, including fenestration of the atrial septum
and balloon dilation of a pathway obstruction.
In our patient population, 52 (45.6%) patients
were treated noninvasively, 52 (45.6%) patients
received a surgical intervention, and 10 (8.8%)
patients received a percutaneous intervention.
Medical treatment only was given to 52 patients.
An overview of treatments used in this group is
shown in Table V. Most patients were treated with a
combination of diuretics, digoxin, afterload reduc-
tion, and diet. Albumin infusions were given inter-
mittently in 28 of 52 patients. Additional medication
was given to 32 of 52 patients. This medical ap-
proach resulted in a subjective improvement with
resolution of the PLE symptoms in 13 of 52 (25%)
patients. In 15 of 52 (28.8%) patients some improve-
ment was observed, but the patients remained symp-
tomatic (alive with PLE). Twenty-four (46.2%) pa-
tients from this treatment group died.
Surgery was performed in 52 of 114 patients. The
median interval between the diagnosis of PLE and
surgery was 1.0 year (range: 0.01 to 8.0 years). The
median age at operation was 14.6 years (range: 2.5
to 45.3 years). The interval between the Fontan
operation and the redo operation for PLE was 4.5
years (range: 0.6 to 16.5 years). A wide variety of
surgical approaches were tried (Table VI). The first
type of operation was surgery aimed at optimizing
the Fontan circuit either by conduit surgery, valve
surgery, or ventricular septal defect surgery. A sec-
ond type of operation involved the conversion of a
type of Fontan circuit (for example, atrioventricular
connection converted into atriopulmonary connec-
tion). This operation was performed either because
of a mechanical problem with the existing Fontan
circuit or because the new type of circuit was
thought to be hemodynamically more favorable. A
third type of operation is defined as a Fontan
takedown. In a fourth subgroup of patients, heart
transplantation was performed.
Table IV. PLE hemodynamic data
Number Mean SD Minimum Maximum
Sat Ao 60 90.1 6.7 63.0 99.0
Sat MV 56 64.0 8.8 41.0 71.0
RAP 79 17.0 5.3 8.0 38.0
PAP 77 16.3 6.1 6.0 40.0
VEDP 59 9.5 5.6 0.0 37.0
PVR 30 2.9 1.6 0.3 7.7
CI 53 2.4 0.8 0.6 5.9
SD, Standard deviation; Sat Ao, saturation aorta; Sat MV, mixed venous
saturation; RAP, mean right atrial pressure; PAP, mean pulmonary artery
pressure; VEDP, ventricular end-diastolic pressure; PVR, pulmonary vas-
cular resistance; CI, cardiac index.
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The outcome of surgery is presented in Table VII.
A very high overall mortality rate (61.5%) is associ-
ated with PLE surgery. Most of the deaths occur in
the early postoperative period (81% within 3
months after the operation). Although the groups
are relatively small, all different surgical approaches
seem to result in a poor outcome. Even heart
transplantation appeared to have a high mortality
rate, with two deaths in five patients. There is also
one patient in whom the PLE symptoms did not
resolve after transplantation.
In 13 patients interventional catheterization were
performed. In three patients the interventional ap-
proach was combined with a surgical approach.
Three types of interventional procedures were per-
formed in the patients with PLE. The first type
involved a balloon dilation with or without stenting
of a stenosis on the Fontan-type connection or of a
stenosis on the pulmonary artery (nine interven-
tions). The second type of intervention involved
percutaneously creating a fenestration in the intra-
atrial septum (five interventions). In one patient,
systemic–pulmonary artery collaterals were oc-
cluded with coils.
Nine balloon dilations with four stent placements
were performed, three because of a stenosis in the
Fontan circuit and six for a stenosis in a pulmonary
artery. The mean gradient before balloon dilation
was 4.8 6 4.4 mm Hg that was reduced to 2.0 6 1.9
mm Hg after the procedures. In eight cases the
procedure was considered successful with a signifi-
cant decrease in gradient or in increase in blood
flow. In one patient a balloon dilation of the inferior
cavopulmonary anastomosis was unsuccessful with
no reduction in gradient. Of the eight successful
procedures, three had no effect on PLE and three
resulted in a long-lasting symptomatic improvement
(in one patient this occurred after further surgery);
in two patients only a temporary improvement was
obtained with a recurrence of PLE symptoms within
a few months after the procedure.
Five fenestrations in the intraatrial septum were
created percutaneously with different techniques. In
three patients the fenestration was created by blade
septectomy combined with progressive balloon dila-
tion of the fenestration. In one patient the intra-
atrial septum was punctured, and progressive bal-
loon dilations of the puncture hole were performed.
In one patient a stent was placed in the fenestration.
The time interval between the diagnosis of PLE and
the fenestration was 1.6 years (median range: 0.2 to
5.1 years). The median age at fenestration was 17.9
years (range: 2.8 to 41.7 years). The median time
interval between the creation of the fenestration and
the time of Fontan surgery was 8.5 years (range: 1.6
to 10.7 years). In three of the five patients a marked
effect was observed on the PLE symptoms with
nearly complete resolution of all symptoms. In the
remaining two patients only a mild improvement
was observed. In two patients a stroke occurred after
the fenestration was created. One of these patients
was not given anticoagulants after the fenestration.
Fig. 1. Survival analysis (Kaplan-Meier) of patients with PLE. The graph represents a Kaplan-Meier
survival analysis. Time zero represents the date of diagnosis of PLE. The vertical bars represent the 95%
confidence interval.
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In one patient systemic–pulmonary artery collat-
erals were closed by coil placement, but this did not
improve intestinal protein loss.
Fig. 2 represents the Kaplan-Meier survival anal-
ysis for the three different treatment groups. Log
rank analysis could not demonstrate a significant
effect of treatment option on PLE survival (Table
VIII).
The effect of steroid treatment on PLE. Because
steroids have been added to the treatment in the
different treatment groups, their effect on PLE is
discussed separately. Steroids have been added to
the treatment in 16 patients. Seven patients in the
surgical treatment group received steroids: five pa-
tients before the intervention and two patients after
the operation. It is evident that in those patients in
whom surgery was performed after steroid treat-
ment, steroid treatment was not sufficiently effec-
tive. Six patients of the interventional catheteriza-
tion group were also treated with steroids. Four
patients received steroids after the intervention and
two patients before it. In three patients of the
medication-only group, steroids were added to the
treatment. All patients were treated with reducing
dosing schemes. Steroid treatment resulted in a
marked symptomatic improvement in 5 of 16 pa-
tients, with nearly complete disappearance of all
PLE symptoms. Four of these patients, however,
required prolonged administration of a low mainte-
nance dose. In 7 of 16 patients some subjective
symptomatic improvement was obtained without
complete disappearance of all PLE symptoms. In
four patients no effect could be noted.
Discussion
This multicenter study summarizes the clinical
characteristics and treatment outcomes of patients
with PLE after Fontan-type surgery. It confirms that
PLE is a rare complication after Fontan-type sur-
gery that is associated with a poor prognosis. What-
ever treatment strategy is used, the prognosis of
patients with PLE after Fontan-type surgery is poor.
Clinical characteristics of patients in whom PLE
develops after Fontan surgery. In a recent study
Feldt and associates1 overviewed the clinical char-
acteristics of the Mayo Clinic patients in whom PLE
developed after a Fontan operation. They studied a
total of 427 patients who survived for 30 days after a
Fontan operation performed between July 1973 and
January 1987. In 47 of 427 (11%) patients PLE
developed during follow up. Univariate and multi-
variate analysis indicated that the factors associated
with the development of PLE were ventricular anat-
omy (other anatomy than dominant left ventricle),
increased preoperative ventricular end-diastolic
pressure, longer operative bypass time, increased
length of hospital stay, and postoperative renal
failure. In the present study a multivariate analysis
could not be performed because the data on the
patients in whom PLE did not develop after Fontan
surgery could not be obtained. However, in the
patients described in the present study (which also
includes the Mayo Clinic data), several of these risk
factors seem to be present.
The preoperative hemodynamic evaluation shows
that some of the patients in whom PLE develops
Table V. Overview of medical treatment
Treatment
No. of patients
receiving
medical
treatment only*
(%)
Total no.
of patients in
PLE group†
Diuretics 51 (98) 109 (96)
Furosemide only 19 41
Spironolactone only 1 4
Furosemide 1
Spironolactone
30 62
Other 1 2
Positive inotropic agents 42 (81) 91 (80)
Digoxin/digitoxin 42 87
Dopamine 0 3
Afterload reduction 37 (71) 67 (59)
ACE-I 32 61
Hydralazine 2 2
Other 3 4
Steroids 3 (5.7) 16 (14)
Hydrocortisone 0 1
Prednisone 0 7
Prednisolone 0 4
Methylprednisolone 3 4
Protein infusions 28 (54) 67 (59)
Albumin 20% 24 61
Gamma globulins 5 8
Plasma 1 2
Diet 42 (81) 79 (69)
High protein 29 61
Low fat 21 43
High protein–low fat 18 32
MCT 6 15
Other medication 32 (61) 60 (53)
Anticoagulants 7 19
Aspirin 7 17
Antiarrhythmics 14 33
Other 3 5
ACE-I, Angiontensin-converting enzyme inhibitors; MCT, medium-chain
triglycerides.
*N 5 52.
†N 5 114.
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after Fontan surgery would nowadays no longer be
scheduled for Fontan surgery (for instance, a patient
with a pulmonary vascular resistance of 5.6 units/m2
or a patient with a mean pulmonary artery pressure
of 41 mm Hg). Because some of these patients had
been initially treated in the pre-Fontan era, the
pre-Fontan palliations used reflect a historical evo-
lution in the treatment of univentricular hearts. This
is demonstrated by the wide variation of different
initial palliative techniques, with some patients hav-
ing had suboptimal pre-Fontan procedures with
poor timing (banding at 0.9 6 0.9 year). This
resulted in prolonged and excessive volume loading
of the ventricle and elevated pulmonary vascular
resistance in some of the later patients with PLE.
This certainly contributed to a difficult early postop-
erative course in some of these patients (such as,
with pleural effusions, renal failure). Although we
have no reference values, a mean hospitalization
stay of 26 days seems long after a Fontan operation.
Remarkable in the present study is the predom-
inance of patients with a left ventricular morpho-
logic condition (68%), with only 18% of all pa-
tients with PLE having a right ventricular
morphologic condition. In 14% of all patients
ventricular morphologic condition could not be
determined. This distribution is to be compared to
the whole Fontan population, but it shows that
further study is required to better identify the risk
factors associated with PLE.
PLE hemodynamics and pathophysiology. PLE
in cardiac disease is mostly associated with disorders
in which chronically elevated systemic venous pres-
sures and especially elevated superior caval venous
pressures are present (constrictive pericarditis,4
long-standing congestive heart failure,5 baffle ob-
struction after the Mustard operation for transposi-
tion of the great arteries6; after the Glenn opera-
tion7 and Fontan operation1, 2, 8-11). The exact
pathophysiology of PLE is unknown. It is hypothe-
sized that chronic venous congestion with elevated
superior vena caval pressures leads to disturbed
lymph drainage through the thoracic duct.10 More-
over, the increased inferior vena caval and portal
vein pressures lead to increased intestinal conges-
tion and lymph production. Proteins and lympho-
cytes leak from the dilated lymphatics. This func-
tional disorder may progress to intestinal
lymphangiectasia. Maybe an inflammatory response
caused by chronic congestion or leakage of proteins
from the enteric lymphatic system is also involved in
the pathogenetic process. The beneficial therapeutic
effect of steroids observed in some patients could be
explained by suppression of this inflammatory reac-
tion.12-14 No consistent effect of steroids can, how-
ever, be found, which indicates that additional
mechanisms are probably involved. The actual mo-
lecular basis for PLE remains unknown. It has been
shown that sulphated glycosaminoglycans may be
important in regulating vascular and renal albumin
loss. In a recent paper three children with PLE were
shown to have an enteric heparin sulfate deficien-
cy.15 In those three infants a complete absence of
enterocyte heparin sulphate was found by histo-
chemistry. The recent finding that high molecular-
weight heparin improves PLE after the Fontan
operation19 could be consistent with this. Chronic
congestion could interfere with the production and
distribution of heparin sulfate leading to intestinal
albumin loss. Another possibility is a disturbance in
endothelial function in the lymphatic system. The
exact pathophysiologic mechanism presently re-
mains obscure and requires further study. Especially
the impact of chronically elevated systemic venous
Table VI. Different types of operations
Type of operation
No. of
patients
Optimizing Fontan circuit 26
Conduit surgery 12
Conduit surgery 1 atrioventricular valve replace-
ment
1
Plasty tricuspid valve 1
Plasty mitral valve 1 ASD closure 1
Plasty mitral valve 1 VSD closure 1
Atrioventricular valve replacement 1 subaortic
stenosis resection
2
Closure ventricle–pulmonary artery connection 3
Patch enlargement pulmonary artery 2
Surgical closure atrioventricular valve 1
VSD enlargement 1
Excision intraatrial patch hepatic veins–pulmo-
nary artery
1
Conversion-type Fontan circuit 13
RAPA . TCPC 5
RAPA . fenestrated RAPA 1
RAPA . CPAP 1
RARV . RARV 1 BDG 1
RARV . RAPA 3
CPAP . fenestrated TCPC 1
TCPC . fenestrated TCPC 1
Fontan takedown 4
Heart transplantation 5
Other interventions 4
ASD, Atrial septal defect; VSD, ventricular septal defect; RAPA, right
atrial to pulmonary connection; TCPC, total cavopulmonary connection;
CPAP, cavopulmonary atriopulmonary connection; RARV, right atrial to
right ventricle connection; BDG, bidirectional Glenn.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 115, Number 5
Mertens et al. 1 0 6 9
pressures on intestinal lymphatic functioning should
further be explored in experimental studies.
Because systemic venous pressure is the driving
force for the pulmonary circulation in a Fontan
circulation, chronic venous congestion is always
present. It is not known why intestinal protein loss
therefore occurs in a small percentage of patients.
Our data suggest that not only hemodynamic factors
are involved in the process of PLE but that the
complication may result from a combination of
unfavorable factors. Increased systemic venous pres-
sures are certainly not the only underlying factor
because, in 23% of the patients with PLE in whom
right atrial pressures were obtained, mean right
atrial pressure was below 15 mm Hg (a “good” value
for a patient after a Fontan operation). Even in
those patients where an unfavorable hemodynamic
factor was detected on hemodynamic evaluation
(e.g., stenosis on the conduit), improvement of the
hemodynamics (e.g., removal of the stenosis) did
not always result in improvement of PLE. These are
patients in whom the Fontan circulation is not
tolerated without any good explanation. It may be
that the intestinal lymphatic system operates at the
limit of its capacities in all patients after the Fontan
operation but only fails in a small percentage of
patients. Structural and physiologic differences in
lymphatic function could explain the occurrence of
PLE but these are extremely difficult to study.
Another possibility is that the standard hemody-
namic evaluation methods in these patients fail
to uncover hemodynamic disturbances causing
PLE. Especially the evaluation of right atrial
pressures and pulmonary vascular resistance in
patients who have been aggressively treated with
diuretics before the cardiac catheterization is
questionable. Other factors such as pulmonary
vascular reactivity may not be adequately evalu-
ated during catheterization.
PLE treatment and outcome. Different treatment
options have been tried in patients in whom PLE
develops after the Fontan operation, but only a few
successful approaches have been published.12-14, 16-20
Our patients experienced a wide variety of differ-
ent treatment strategies. To organize the different
treatment options, we categorized our patients into
three different classes: purely medical treatment,
surgical treatment, and treatment by interventional
catheterization. This division is somewhat arbitrary,
because all patients who underwent surgical treat-
ment were also receiving medication. Moreover the
“surgery” group is a very heterogeneous group going
from Fontan redo surgery to Fontan takedown and
heart transplantation. No relation between strategy
and outcome of PLE was observed.
Medical treatment was aimed at some symptom-
atic relief (diuretics, intermittent infusion of albu-
min) to improve hemodynamics (digitalis, ventricu-
lar afterload reduction), to influence an unknown
mechanism (steroids), or to prevent further compli-
cations (antiarrhythmics, anticoagulation). Results
were disappointing, and this probably reflects, in
most cases, the natural history of PLE after the
Fontan operation.
Surgery in patients with PLE was associated with
a very high mortality rate. Especially in patients with
ventricular dysfunction, atrioventricular-valve insuf-
ficiency, or increased pulmonary vascular resistance,
mortality rate is extremely high. Poor hemodynam-
ics and chronic hypoproteinemia with resulting ca-
tabolism probably compromised the outcome of
major cardiac surgery. In this context it should be
noted that a long time interval between the diagno-
sis of PLE and the time of surgery was observed in
the present study (mean: 1.8 years; range: 0.01 to 8.0
years). Reluctance of the cardiologist or the surgeon
to perform major surgery in a “mildly” symptomatic
patient probably caused a major delay in many
cases. Of those patients with PLE who survived
surgery, only 50% were cured of PLE after surgery.
This could be due to insignificant improvement in
hemodynamics after surgery. So, for instance, con-
verting one type of Fontan circulation into another
Table VII. Outcome of surgery
Type of surgery Death
Alive
with PLE
Alive
no PLE Total
Optimizing Fontan 17 5 4 26
Conversion Fontan 6 4 3 13
Takedown 3 0 1 4
Cardiac transplant 2 1 2 5
Other 4 0 0 4
Total (%) 32 (61.5) 10 (19.2) 10 (19.2) 52
PLE, Protein-losing enteropathy.
Table VIII. Final outcome of PLE
Death
(%)
Alive 1
PLE
(%)
Alive no
PLE
(%) Total
Medical treatment 24 (46.2) 15 (28.8) 13 (25) 52
Intervention 1 (10) 5 (50) 4 (40) 10
Surgery 32 (61.6) 10 (19.2) 10 (19.2) 52
Total 57 (50) 30 (26) 27 (24) 114
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type of circuit may not result in a hemodynamic
amelioration that is sufficient to cure PLE. In vitro
hemodynamic studies and computer simulations
have shown that some types of Fontan circuits are
hemodynamically more favorable than others.20-23 It
seems that if a patient is not tolerating one type of
circuit, the small differences in energy loss between
the different surgical connections may not really be
clinically relevant. Also the changes in the enteric
system may become irreversible and not responsive
even to normalization of the hemodynamics. In one
cardiac transplant patient, PLE resolved completely
in the immediate postoperative period but recurred
a few years after surgery despite good hemodynam-
ics. Thus the effect of transplantation on PLE after
Fontan surgery also requires further study.
Because of the high risk associated with surgery,
interventional procedures to optimize the Fontan
circuit are a potential alternative. Different types of
interventions were performed. The balloon dilations
and stent placements resulted in symptomatic im-
provement in most patients. However, only one
patient was actually considered as not having symp-
tomatic protein loss after the procedure. Previous
reports have already mentioned a beneficial effect of
fenestrating the intraatrial septum on PLE.16-18, 24
This is confirmed in the present study where a
fenestration was performed with improved Fontan
hemodynamics in five patients and reduced protein
loss after the procedure in all patients. It is the only
treatment where a consistent positive effect was
observed. However, in two patients a thromboem-
bolic event occurred with neurologic complications
that indicated the absolute requirement for antico-
agulation before and after the fenestration. More-
over, there was a high tendency for the percutane-
ous fenestrations to close spontaneously with
deterioration of PLE symptoms. Newer techniques
like stent placement in the intraatrial septum could
prevent this, but only limited experience is presently
available.25
Limitations of the study. It is evident that this
study has the limitations of any multicenter clinical
study, such as center differences in patient evalua-
tion. Moreover, this study has the limitations of any
retrospective study that comprises incompleteness
of data, making conclusions very difficult. An addi-
tional limitation is the absence of a control group of
patients who underwent a Fontan operation and in
whom PLE did not develop. Ideally we should have
obtained data on all 2854 patients who are still in
follow-up in the 35 participating centers, but this
was practically unfeasible. Maybe the creation of an
international Fontan registry could help for studying
more rare complications of this operation.
Conclusion: Therapeutic strategies for PLE after
Fontan surgery
Because enteric lymphatic function is impossible
to evaluate, only the Fontan hemodynamics can be
directly assessed after the diagnosis of PLE is made.
Therefore, the moment the diagnosis is suspected,
Fig. 2. Survival analysis of different treatment groups. A Kaplan-Meier analysis of the different treatment
subgroups is represented. Time zero represents the date of diagnosis of PLE. Log rank analysis did not show
a significant effect of treatment on survival.
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an immediate, careful, complete hemodynamic eval-
uation with catheterization is required. When a
hemodynamic lesion that can be treated by thera-
peutic intervention (e.g., pulmonary artery stenosis)
is detected, this should be immediately managed.
Fenestration should be considered if there is no
residual lesion to treat. Full anticoagulation is indi-
cated before and after the fenestration. Surgery
should be performed before cachexia develops. Sig-
nificant ventricular dysfunction or atrioventricular
valve regurgitation are important contraindications
for reoperation. The patient’s general condition
should be optimized before surgery. A trial with
high-dose steroid treatment or subcutaneous high
molecular weight heparin may be used. Heart trans-
plantation should be considered before chronic PLE
with eventual irreversible changes in the enteric
lymphatic system develops.
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